NewAmsterdam Pharma Announced Dosing Of The First Patient And Initiation Of TANDEM Phase 3 Trial To Evaluate Obicetrapib And Ezetimibe FDC In Adult Patients With Heterozygous Familial Hypercholesterolemia And/Or Atherosclerotic Cardiovascular Disease
新阿姆斯特丹制药公司宣布为第一位患者服药并启动TANDEM 3期试验,以评估杂合子家族性高胆固醇血症和/或动脉粥样硬化性心血管疾病的成年患者的奥比曲匹和依泽替米贝FDC